Greenfield

Researchers are evaluating patient-reported outcomes and functional scores before and after an all-arthroscopic Brostrom repair for lateral ankle ligament injuries. The study compares two surgical approaches: using suture anchors alone versus suture anchors combined with a BioBrace implant. This investigation aims to better understand the effects of adding the BioBrace implant on recovery and ankle stability. Participants are randomly assigned to one of two groups: the control group receives arthroscopic Brostrom repair with suture anchors only, while the treatment group receives the repair with suture anchors augmented by the BioBrace implant. The procedure is performed using an all-arthroscopic Brostrom technique. Both groups undergo the same surgical approach except for the use of the implant in the treatment group. Participants will be assessed before surgery and then followed up at 1, 3, and 6 weeks, as well as 3, 6, and 12 months after surgery. Evaluations include several patient-reported outcome measures to assess pain, foot function, ankle stability, and activity levels. These assessments include the American Orthopedic Foot and Ankle Society score, Foot Function Index, Visual Analog Scale, and Karlsson-Peterson score. The study also monitors safety and recovery throughout the year-long follow-up.

Researchers are investigating whether the medicine vicadrostat, when taken together with empagliflozin, can lower the risk of heart-related problems in adults who have type 2 diabetes, high blood pressure, and cardiovascular disease but no history of heart failure. This study is a Phase III trial that compares the effects of vicadrostat plus empagliflozin to a placebo plus empagliflozin in people with these conditions. Participants are randomly assigned to one of two groups: one group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets that look like vicadrostat along with empagliflozin. All participants take one tablet daily for a period ranging from two and a half years up to four years and three months. Throughout the study, participants continue their usual medications for diabetes, high blood pressure, and cardiovascular disease. During up to 51 months of participation, participants visit the study site regularly where doctors collect health information and blood samples. Researchers track when participants experience cardiovascular events such as heart-related deaths or heart failure events. The study also monitors participants’ overall health and any side effects they may experience to assess the safety and effects of the treatments.

Researchers are evaluating whether the drug zilebesiran can reduce the risk of major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults who have hypertension that is not well controlled and who either have established cardiovascular disease or are at high risk for it. This Phase 3 global study is designed to continue until enough cardiovascular events have occurred to assess the treatment's effect. Participants will be randomly assigned to receive either zilebesiran or a placebo, both given as injections under the skin (subcutaneous administration). All participants will continue with their standard care, which includes treatment with at least two antihypertensive medications, one of which must be a diuretic such as a thiazide or loop diuretic. The study is double-blind, so neither participants nor researchers know who is receiving the active drug or placebo. During the study, participants will be closely monitored for cardiovascular events including heart attacks, strokes, heart failure hospitalizations, and cardiovascular deaths over approximately five years. Researchers will collect data on these events to determine the time until the first occurrence of any of these outcomes. Safety assessments and standard clinical evaluations will also be performed throughout the study period to ensure participant well-being.